Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jeremy Chuang"'
Autor:
Jeremy Chuang, Samuel Klempner, Kevin Waters, Katelyn Atkins, Joseph Chao, May Cho, Andrew Hendifar, Alexandra Gangi, Miguel Burch, Pareen Mehta, Jun Gong
Publikováno v:
Diseases, Vol 10, Iss 2, p 23 (2022)
Gastroesophageal cancer is one of the most common cancers in the world, with a high rate of mortality. While there has been significant progress over the past decade, particularly with the addition of anti-HER2 therapies to platinum-based chemotherap
Externí odkaz:
https://doaj.org/article/70e924d8d3cf490d9862cc18e91ce4ed
Autor:
Jun Gong, Andrew Hendifar, Richard Tuli, Jeremy Chuang, May Cho, Vincent Chung, Daneng Li, Ravi Salgia
Publikováno v:
Clinical and Translational Medicine, Vol 7, Iss 1, Pp 1-16 (2018)
Abstract Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly res
Externí odkaz:
https://doaj.org/article/c053cfdb33884e4eb8430dd7526239dd
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Acute disseminated intravascular coagulation (DIC) is a pathological process involving dysfunction of the coagulation cascade. In this case report, we discuss a 33-year-old woman with BRAF V600E-mutated metastatic melanoma who presented in fulminant
Externí odkaz:
https://doaj.org/article/674bac8a94914f2abc00293694253f45
Publikováno v:
J Gastrointest Oncol
Extrapulmonary small cell carcinoma (EPSCC) is a rare and aggressive clinical entity that can involve a variety of anatomic locations, including the gastrointestinal tract. Involvement of the gastrointestinal tract is associated with a particularly p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b369992be3a753ce72106a44b4786043
https://doi.org/10.21037/jgo-21-434
https://doi.org/10.21037/jgo-21-434
Publikováno v:
Clinical Colorectal Cancer. 20:72-78
Background MAP2K1 mutations, otherwise known as MEK mutations, are rare oncogenic alterations that have been implicated in MAPK pathway activation. The impact of MAP2K1 mutations in colorectal cancer on EGFR antibody response has not been characteriz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb4609381fcc3a8127ddb8291b9bcb8e
https://doi.org/10.1016/j.clcc.2020.12.003
https://doi.org/10.1016/j.clcc.2020.12.003
Publikováno v:
Clinical colorectal cancer. 21(3)
e15579 Background: TAS-102 was approved in 2015 after the phase III RECOURSE clinical trial demonstrated a modest improvement in overall survival in refractory metastatic colorectal cancer (mCRC). Preclinical models have shown synergistic activity be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8408bdc6e69c385909efd7678da3f9
https://pubmed.ncbi.nlm.nih.gov/35738999
https://pubmed.ncbi.nlm.nih.gov/35738999
Publikováno v:
International Journal of Molecular Sciences, vol 21, iss 15
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 5232, p 5232 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 5232, p 5232 (2020)
Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer mortality worldwide. While significant advances have been made for the treatment of advanced hepatocellular carcinoma in the past few years, the prognosis remains poor and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5593d44f577c341df90cf68b12ea97
https://escholarship.org/uc/item/0wk3t3xd
https://escholarship.org/uc/item/0wk3t3xd
Autor:
Vincent Chung, Richard Tuli, Andrew Eugene Hendifar, Jun Gong, Jeremy Chuang, Ravi Salgia, Daneng Li, May Cho
Publikováno v:
Clinical and Translational Medicine, Vol 7, Iss 1, Pp 1-16 (2018)
Clinical and translational medicine, vol 7, iss 1
Clinical and Translational Medicine
Clinical and translational medicine, vol 7, iss 1
Clinical and Translational Medicine
Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly resistant to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::151b0bcba83e49a21b8544dc760ea199
http://link.springer.com/article/10.1186/s40169-018-0210-9
http://link.springer.com/article/10.1186/s40169-018-0210-9
Publikováno v:
Journal of Gastrointestinal Oncology. 9:560-572
The multidisciplinary management of locoregional esophagogastric cancers (GCs) has evolved significantly over the past two decades. While perioperative chemotherapy, adjuvant chemotherapy, and postoperative chemotherapy with chemoradiation (CRT) have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6f1ce77ddeabc49a4154c44d1386412
https://doi.org/10.21037/jgo.2018.03.01
https://doi.org/10.21037/jgo.2018.03.01
Publikováno v:
Translational gastroenterology and hepatology, vol 4, iss August
The development of checkpoint inhibitors has redefined the treatment paradigm for advanced gastroesophageal cancer. While recent developments have improved clinical outcomes, the prognosis for the disease remains meager. In this review, we discuss th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b2d03ca29e01a1d9f8e1e12c8c1e6fc
https://pubmed.ncbi.nlm.nih.gov/31559344
https://pubmed.ncbi.nlm.nih.gov/31559344